DGIdb - PDGFRB Gene Record

PDGFRB 5159 Druggable GenomeClinically Actionable

Alternate Names:

5159
PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA
PDGFRB
CD140B
IBGC4
IMF1
JTK12
KOGS
PDGFR
PDGFR-1
PDGFR1
PENTT
173410
8804
ENSG00000113721
OTTHUMG00000130053
P09619
PGFRB_HUMAN
CD140 antigen-like family member B
Platelet-derived growth factor receptor beta
Beta platelet-derived growth factor receptor
Beta-type platelet-derived growth factor receptor
PDGFR-beta
PDGF-R-beta
CD_antigen=CD140b
Platelet-derived growth factor receptor 1
BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619]
4176
PA33148
T59102

Gene Info:

Target Subclass	KInase
Target Main Class	Receptors
Transmembrane Helix Count	1
Target Subclass	PDGFR
Interpro Acc	IPR001245
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	KINASE
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Uniprot Status	Swiss-Prot
Human Readable Name	DRUGGABLE GENOME
Interpro Type	Domain
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(21 More Sources)

Gene Categories: Category Details

CELL SURFACE
KINASE
TYROSINE KINASE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep
Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal
Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer
Guida et al., 2007, Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants., Clin. Cancer Res.
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
David et al., 2007, Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders., Blood
Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol
Lengline E et al., 2013, Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion., Haematologica
Weston et al., 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J. Clin. Oncol.
Jones et al., 2005, The development and application of imatinib., Expert Opin Drug Saf
Modi et al., 2005, A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer., Breast Cancer Res. Treat.
Johnson et al., 2005, Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells., J. Cell. Physiol.
Basciani et al., 2005, Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity., Cancer Res.
Chen et al., 2006, The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression., Cancer Lett.
Ishibashi T et al., 2016, Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells., Exp Hematol
Chen et al., 2006, Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)., Mol. Pharmacol.
Zhang et al., 2006, New assignments for multitasking signal transduction inhibitors., Mol. Pharmacol.
Lindauer et al., 2010, Dasatinib., Recent Results Cancer Res.
Zhang G et al., 2017, Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report., Am J Case Rep
Xiao W et al., 2018, A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure., Onco Targets Ther
Pietras et al., 2005, A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer., J. Clin. Oncol.
Barattè et al., 2004, Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction., J Chromatogr A
Abrams et al., 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer., Mol. Cancer Ther.
Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.
Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging
Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.
Millward MJ et al., 2006, The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study., Br J Cancer
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem

BECAPLERMIN PDGFRB

Interaction Score: 2.18

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor agonist

Direct Interaction yes

Trial Name becaplermin,Regranex

PMIDs:
18686746

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
PETROSIOL A PDGFRB

Interaction Score: 1.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23415061

Sources:
DTC
CDP-860 PDGFRB

Interaction Score: 0.87

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TELATINIB PDGFRB

Interaction Score: 0.58

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name telatinib

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
BAFETINIB PDGFRB

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26703895

Sources:
CIViC
MOTESANIB PDGFRB

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions
REBASTINIB PDGFRB

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26703895

Sources:
CIViC
X-82 PDGFRB

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
TAK-593 PDGFRB

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
JI-101 PDGFRB

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
XL-820 PDGFRB

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD
SUNITINIB PDGFRB

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Sutent

Novel drug target Established target

PMIDs:
29760553 16425993 15557593 14753710 12748309 12538485 19248971

Sources:
TALC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB
VATALANIB PDGFRB

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions
TANDUTINIB PDGFRB

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions
FAMITINIB PDGFRB

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD
NINTEDANIB PDGFRB

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial
IMATINIB PDGFRB

Interaction Score: 0.25

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name imatinib mesylate, STI 571,Gleevec, Glivec

Novel drug target Established target

PMIDs:
16960151 32068648 24186319 23835704 15794712 15803362 15887238 15753388 15893416 26703895

Sources:
DTC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB FDA OncoKB
NILOTINIB PDGFRB

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26703895

Sources:
CIViC MyCancerGenomeClinicalTrial
AXITINIB PDGFRB

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name axitinib, AG-013736

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
CM-082 PDGFRB

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ORANTINIB PDGFRB

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions
MASITINIB PDGFRB

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

Direct Interaction yes

PMIDs:
None found

Sources:
TdgClinicalTrial ChemblInteractions MyCancerGenomeClinicalTrial
ANLOTINIB PDGFRB

Interaction Score: 0.17

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PONATINIB PDGFRB

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20513156 26703895

Sources:
DTC CIViC
PEGPLERANIB SODIUM PDGFRB

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E-10030

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
CRENOLANIB PDGFRB

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SORAFENIB PDGFRB

Interaction Score: 0.14

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Notes

PMIDs:
17619763 16425993 17545544 28362716

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB TTD
DASATINIB PDGFRB

Interaction Score: 0.14

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Trial Name dasatinib, BMS-354825,Sprycel

PMIDs:
16436588 16497876 20072833 26703895 29133777

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND CIViC MyCancerGenomeClinicalTrial
AMUVATINIB PDGFRB

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MP-470

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
REGORAFENIB PDGFRB

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions MyCancerGenomeClinicalTrial
SU-014813 PDGFRB

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
ROMIPLOSTIM PDGFRB

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
PAZOPANIB PDGFRB

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
17288876

Sources:
TALC DTC MyCancerGenome MyCancerGenomeClinicalTrial
SUNITINIB MALATE PDGFRB

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BARASERTIB PDGFRB

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
NINTEDANIB ESYLATE PDGFRB

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
QUIZARTINIB PDGFRB

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
IMATINIB MESYLATE PDGFRB

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PAZOPANIB HYDROCHLORIDE PDGFRB

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PUQUITINIB PDGFRB

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
XL-999 PDGFRB

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
FORETINIB PDGFRB

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LENVATINIB PDGFRB

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E7080

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
MK-2461 PDGFRB

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
MIDOSTAURIN PDGFRB

Interaction Score: 0.07

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
16969355

Sources:
ChemblInteractions
CEDIRANIB PDGFRB

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC DTC ChemblInteractions
SORAFENIB TOSYLATE PDGFRB

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
TG100-801 PDGFRB

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
RABEPRAZOLE SODIUM PDGFRB

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CEP-2563 PDGFRB

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LINIFANIB PDGFRB

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name ABT-869, Linifanib

Novel drug target Established target

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
DTC MyCancerGenome TdgClinicalTrial ChemblInteractions
DORAMAPIMOD PDGFRB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOVITINIB PDGFRB

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name dovitinib, TKI-258, CHIR-258

Novel drug target Established target

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions
AZD-1152-HQPA PDGFRB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PD-0166285 PDGFRB

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC ChemblInteractions
ENMD-981693 PDGFRB

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
CHEMBL406845 PDGFRB

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CHEMBL546797 PDGFRB

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
AST-487 PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
HESPERADIN PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19035792

Sources:
DTC
SNS-314 PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RG-1530 PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
DTC ChemblInteractions
OSI-632 PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
DTC ChemblInteractions
VANDETANIB PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SOTRASTAURIN PDGFRB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOZASERTIB PDGFRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
R-406 PDGFRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 PDGFRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-00562271 PDGFRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB PDGFRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

Ensembl: ENSG00000113721
- Version: 101_38
Alternate Names:

PDGFRB Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P09619
- Version: 01-August-2011
Alternate Names:

ENSG00000113721 Ensembl Gene Id

PDGFRB Gene Symbol

PGFRB_HUMAN Uniprot Id

Gene Info:

Target Subclass KInase

Target Main Class Receptors

Transmembrane Helix Count 1

Publications:
HopkinsGroom: P09619
- Version: 11-September-2012
Alternate Names:

PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA Uniprot Protein Name

P09619 Uniprot Accession

5159 Entrez Gene Id

Gene Info:

Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom

Uniprot Evidence 1: Evidence at protein level

Human Readable Name KINASE

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:

RussLampel: ENSG00000113721

Version: 26-July-2011

Alternate Names:

ENSG00000113721 Ensembl Gene Id

BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619] Description

PDGFRB Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TdgClinicalTrial: P09619
- Version: January-2014
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:

PharmGKB: PDGFRB

Version: 18-August-2020

Alternate Names:

PA33148 PharmGKB ID

Gene Info:

Publications:

Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am

Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

CIViC: PDGFRB

Version: 14-September-2020

Alternate Names:

5159 Entrez Gene ID

4176 CIViC Gene ID

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol

Weston et al., 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J. Clin. Oncol.

Ishibashi T et al., 2016, Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells., Exp Hematol

DTC: PDGFRB

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.

Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem

HingoraniCasas: ENSG00000113721
- Version: 31-May-2017
Alternate Names:

ENSG00000113721 Gene Symbol

PDGFRB Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: PDGFRB
- Version: 12-May-2016
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Publications:
MyCancerGenome: PDGFRB
- Version: 20-Jun-2017
Alternate Names:

5159 Entrez Gene Id

PDGFRB MyCancerGenome Gene Symbol

PDGFR-beta MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: PDGFR
- Version: chembl_23
Alternate Names:

PDGFR1 GENE_SYMBOL

PDGFRB GENE_SYMBOL

Platelet-derived growth factor receptor beta UNIPROT

Gene Info:

Publications:
OncoKB: PDGFRB
- Version: 23-July-2020
Alternate Names:

5159 OncoKB Entrez Id

PDGFR1 OncoKB Gene Synonym

KOGS OncoKB Gene Synonym

Gene Info:

Publications:
GO: PDGFRB
- Version: 01-February-2022
Alternate Names:

PDGFR GO Gene Synonym

PDGFR1 GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, TYROSINE KINASE

Publications:
Tempus: PDGFRB
- Version: 11-November-2018
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: PDGFRB
- Version: 27-Jun-2013
Alternate Names:

5159 Gene ID

CD140B dGene Synonym

JTK12 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
TTD: Platelet-derived growth factor receptor beta
- Version: 2020.06.01
Alternate Names:

PDGFRB TTD Gene Abbreviation

T59102 TTD Target ID

Gene Info:

Publications:
Pharos: PDGFRB
- Version: 01-February-2022
Alternate Names:

Platelet-derived growth factor receptor beta Gene Name

P09619 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
ClearityFoundationClinicalTrial: PDGFRB
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MskImpact: PDGFRB
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MyCancerGenomeClinicalTrial: PDGFRB
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: PDGFRB
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: PDGFRB
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FDA: PDGFRB
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:
Oncomine: PDGFRB
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Mechanism of Interaction	Platelet-derived growth factor receptor agonist
Direct Interaction	yes
Trial Name	becaplermin,Regranex

Notes
Novel drug target	Established target
Trial Name	motesanib diphosphate, AMG 706

Notes
Trial Name	BIBF-1120,Vargatef
Novel drug target	Established target

Trial Name	imatinib mesylate, STI 571,Gleevec, Glivec
Novel drug target	Established target

Notes
Trial Name	axitinib, AG-013736
Novel drug target	Established target

Trial Name	masitinib, AB1010
Novel drug target	Established target
Direct Interaction	yes

Trial Name	ABT-869, Linifanib
Novel drug target	Established target
Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor

Trial Name	dovitinib, TKI-258, CHIR-258
Novel drug target	Established target
Mechanism of Interaction	Platelet-derived growth factor receptor inhibitor

ENSG00000113721	Ensembl Gene Id
PDGFRB	Gene Symbol
PGFRB_HUMAN	Uniprot Id

PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA	Uniprot Protein Name
P09619	Uniprot Accession
5159	Entrez Gene Id

antagonist (inhibitory)
inhibitor (inhibitory)

PDGFR1	GENE_SYMBOL
PDGFRB	GENE_SYMBOL
Platelet-derived growth factor receptor beta	UNIPROT

5159	OncoKB Entrez Id
PDGFR1	OncoKB Gene Synonym
KOGS	OncoKB Gene Synonym

Platelet-derived growth factor receptor beta	Gene Name
P09619	UniProt ID

PDGFRB Gene Record

PDGFRB 5159 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor agonist Direct Interaction yes Trial Name becaplermin,Regranex

PMIDs: 18686746

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23415061

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name telatinib Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26703895

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name motesanib diphosphate, AMG 706

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26703895

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name Sutent Novel drug target Established target

PMIDs: 29760553 16425993 15557593 14753710 12748309 12538485 19248971

Sources: TALC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs: None found

Sources: DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

PMIDs: 31016670 18559524

Sources: TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name imatinib mesylate, STI 571,Gleevec, Glivec Novel drug target Established target

PMIDs: 16960151 32068648 24186319 23835704 15794712 15803362 15887238 15753388 15893416 26703895

Sources: DTC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 26703895

Sources: CIViC MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name axitinib, AG-013736 Novel drug target Established target

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor agonist

Direct Interaction yes

Trial Name becaplermin,Regranex

PMIDs:
18686746

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
23415061

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name telatinib

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26703895

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
26703895

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Sutent

Novel drug target Established target

PMIDs:
29760553 16425993 15557593 14753710 12748309 12538485 19248971

Sources:
TALC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC DTC TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

PMIDs:
None found

Sources:
DTC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

PMIDs:
31016670 18559524

Sources:
TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name imatinib mesylate, STI 571,Gleevec, Glivec

Novel drug target Established target

PMIDs:
16960151 32068648 24186319 23835704 15794712 15803362 15887238 15753388 15893416 26703895

Sources:
DTC MyCancerGenome TdgClinicalTrial TEND CIViC PharmGKB FDA OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
26703895

Sources:
CIViC MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name axitinib, AG-013736

Novel drug target Established target

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ChemblInteractions